{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:42:08Z","timestamp":1793655728883,"version":"4.5.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["CTR-QR14-007"],"award-info":[{"award-number":["CTR-QR14-007"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C26866\/A24399"],"award-info":[{"award-number":["C26866\/A24399"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/W017261\/1"],"award-info":[{"award-number":["BB\/W017261\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["23-0146"],"award-info":[{"award-number":["23-0146"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapy has transformed cancer treatment, including early triple-negative breast cancer (TNBC), yet most patients with advanced TNBC fail to respond to immune checkpoint blockade (ICB) plus chemotherapy. Durable control likely requires not only tumour cell killing but also immunogenic cell death (ICD) that activates antitumour immunity. Using a\n                    <jats:italic>Brca1<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u207b\/\u207b<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>p53<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u207b\/\u207b<\/jats:italic>\n                    <\/jats:sup>\n                    organoid-derived TNBC model that recapitulates the immune landscapes of basal-like tumours, we show that RIPK1-driven ICD synergises with anti-PD-1 therapy to induce durable tumour control and immune memory in immune-infiltrated tumours. Mechanistically, both tumour-intrinsic and stromal necroptosis are required. Deletion of\n                    <jats:italic>Ripk1<\/jats:italic>\n                    or\n                    <jats:italic>Mlkl<\/jats:italic>\n                    in tumour cells, or\n                    <jats:italic>Mlkl<\/jats:italic>\n                    in the stromal compartment, markedly impairs therapeutic efficacy. Moreover, immunologically \u201ccold\u201d tumours can be rendered responsive to ICD-based therapy by STING agonists. These findings demonstrate that the benefit of IAP antagonism with checkpoint blockade critically depends on coordinated necroptosis in both tumour and stromal cells, underscoring the need to integrate tumour microenvironmental context when designing ICD-targeted immunotherapies.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-70133-8","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:17:59Z","timestamp":1772810279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Winnie","family":"Fernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2041-5652","authenticated-orcid":false,"given":"Jarama","family":"Clucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsay","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-6130","authenticated-orcid":false,"given":"Crescens","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Layzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Konecnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Wicky John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Jouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1004-3605","authenticated-orcid":false,"given":"Naomi","family":"Guppy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoire","family":"Boulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-3451","authenticated-orcid":false,"given":"Jonathan","family":"Mannion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5100-6663","authenticated-orcid":false,"given":"Chris","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Elshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-1155","authenticated-orcid":false,"given":"Rosa","family":"Andres-Ejarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lumbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Wallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-9748","authenticated-orcid":false,"given":"Ross","family":"Scrimgeour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9960-3896","authenticated-orcid":false,"given":"George","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8684-6095","authenticated-orcid":false,"given":"Martin","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-2716","authenticated-orcid":false,"given":"Andre L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-3949","authenticated-orcid":false,"given":"James M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kolarevic Ivankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Arwert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-7184","authenticated-orcid":false,"given":"Dinis P.","family":"Calado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-201X","authenticated-orcid":false,"given":"Anita","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-1146","authenticated-orcid":false,"given":"Matthew J.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-3380","authenticated-orcid":false,"given":"Alan","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-5480","authenticated-orcid":false,"given":"Syed","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0967-6122","authenticated-orcid":false,"given":"Toby","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Roxanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2901","authenticated-orcid":false,"given":"Andrew N. J.","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tencho","family":"Tenev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-6523","authenticated-orcid":false,"given":"Pascal","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"70133_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"key":"70133_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"CR Heery","year":"2017","unstructured":"Heery, C. R. et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.  Lancet Oncol. 18, 587\u2013598 (2017).","journal-title":"Lancet Oncol."},{"key":"70133_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"70133_CR4","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460\u20132467 (2016).","journal-title":"J. Clin. Oncol."},{"key":"70133_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"70133_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70133_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo, L. et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity 55, 671\u2013685.e610 (2022).","journal-title":"Immunity"},{"key":"70133_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0621-0","volume":"17","author":"S Sousa","year":"2015","unstructured":"Sousa, S. et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 17, 101 (2015).","journal-title":"Breast Cancer Res."},{"key":"70133_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"70133_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"70133_CR11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"70133_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"70133_CR13","doi-asserted-by":"crossref","unstructured":"Reis e Sousa, C. Dendritic cells in a mature age. Nat. Rev. Immunol. 6, 476\u2013483 (2006).","DOI":"10.1038\/nri1845"},{"key":"70133_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nri.2017.9","volume":"17","author":"N Yatim","year":"2017","unstructured":"Yatim, N., Cullen, S. & Albert, M. L. Dying cells actively regulate adaptive immune responses. Nat. Rev. Immunol. 17, 262\u2013275 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"70133_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"70133_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.aad0395","volume":"350","author":"N Yatim","year":"2015","unstructured":"Yatim, N. et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 350, 328\u2013334 (2015).","journal-title":"Science"},{"key":"70133_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41580-022-00564-w","volume":"24","author":"P Vandenabeele","year":"2023","unstructured":"Vandenabeele, P., Bultynck, G. & Savvides, S. N. Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nat. Rev. Mol. Cell Biol. 24, 312\u2013333 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70133_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16887-1","volume":"11","author":"AL Samson","year":"2020","unstructured":"Samson, A. L. et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat. Commun. 11, 3151 (2020).","journal-title":"Nat. Commun."},{"key":"70133_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16819-z","volume":"11","author":"JM Hildebrand","year":"2020","unstructured":"Hildebrand, J. M. et al. A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nat. Commun. 11, 3150 (2020).","journal-title":"Nat. Commun."},{"key":"70133_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","volume":"39","author":"JM Murphy","year":"2013","unstructured":"Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443\u2013453 (2013).","journal-title":"Immunity"},{"key":"70133_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.molcel.2019.09.006","volume":"76","author":"AJ Legrand","year":"2019","unstructured":"Legrand, A. J., Konstantinou, M., Goode, E. F. & Meier, P. The diversification of cell death and immunity: memento mori. Mol. Cell 76, 232\u2013242 (2019).","journal-title":"Mol. Cell"},{"key":"70133_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.it.2019.03.006","volume":"40","author":"N Peltzer","year":"2019","unstructured":"Peltzer, N. & Walczak, H. Cell death and inflammation\u2014a vital but dangerous liaison. Trends Immunol. 40, 387\u2013402 (2019).","journal-title":"Trends Immunol."},{"key":"70133_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcdb.2020.08.007","volume":"109","author":"L Liu","year":"2021","unstructured":"Liu, L. & Lalaoui, N. 25 years of research put RIPK1 in the clinic. Semin. Cell Dev. Biol. 109, 86\u201395 (2021).","journal-title":"Semin. Cell Dev. Biol."},{"key":"70133_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41580-023-00623-w","volume":"24","author":"J Clucas","year":"2023","unstructured":"Clucas, J. & Meier, P. Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. Nat. Rev. Mol. Cell Biol. 24, 835\u2013852 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70133_CR25","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910979","volume":"12","author":"HG Smith","year":"2020","unstructured":"Smith, H. G. et al. RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Mol. Med. 12, e10979 (2020).","journal-title":"EMBO Mol. Med."},{"key":"70133_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4149\/neo_2015_080","volume":"62","author":"P Pluta","year":"2015","unstructured":"Pluta, P. et al. Expression of IAP family proteins and its clinical importance in breast cancer patients. Neoplasma 62, 666\u2013673 (2015).","journal-title":"Neoplasma"},{"key":"70133_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0764-8","volume":"31","author":"YC Xu","year":"2014","unstructured":"Xu, Y. C. et al. Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients. Med. Oncol. 31, 764 (2014).","journal-title":"Med. Oncol."},{"key":"70133_CR28","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/s41418-020-0541-0","volume":"27","author":"N Lalaoui","year":"2020","unstructured":"Lalaoui, N. et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 27, 2768\u20132780 (2020).","journal-title":"Cell Death Differ."},{"key":"70133_CR29","first-page":"2100","volume":"8","author":"M Parton","year":"2002","unstructured":"Parton, M. et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin. Cancer Res. 8, 2100\u20132108 (2002).","journal-title":"Clin. Cancer Res."},{"key":"70133_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-012-2352-6","volume":"137","author":"JL Allensworth","year":"2013","unstructured":"Allensworth, J. L., Sauer, S. J., Lyerly, H. K., Morse, M. A. & Devi, G. R. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res. Treat. 137, 359\u2013371 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"70133_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ceb.2010.08.025","volume":"22","author":"J Lopez","year":"2010","unstructured":"Lopez, J. & Meier, P. To fight or die\u2014inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr. Opin. Cell Biol. 22, 872\u2013881 (2010).","journal-title":"Curr. Opin. Cell Biol."},{"key":"70133_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.molcel.2011.06.006","volume":"43","author":"T Tenev","year":"2011","unstructured":"Tenev, T. et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43, 432\u2013448 (2011).","journal-title":"Mol. Cell"},{"key":"70133_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.molcel.2011.06.011","volume":"43","author":"M Feoktistova","year":"2011","unstructured":"Feoktistova, M. et al. cIAPs block Ripoptosome formation, a RIP1\/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43, 449\u2013463 (2011).","journal-title":"Mol. Cell"},{"key":"70133_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/cdd.2011.163","volume":"19","author":"M Darding","year":"2012","unstructured":"Darding, M. & Meier, P. IAPs: guardians of RIPK1. Cell Death Differ. 19, 58\u201366 (2012).","journal-title":"Cell Death Differ."},{"key":"70133_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-014-0012-4","volume":"17","author":"HM Abdelaal","year":"2015","unstructured":"Abdelaal, H. M. et al. Comparison of vibratome and compresstome sectioning of fresh primate lymphoid and genital tissues for in situ MHC-tetramer and immunofluorescence staining. Biol. Proced. Online 17, 2 (2015).","journal-title":"Biol. Proced. Online"},{"key":"70133_CR36","doi-asserted-by":"publisher","first-page":"e21556","DOI":"10.1371\/journal.pone.0021556","volume":"6","author":"N M\u00fcller-Sienerth","year":"2011","unstructured":"M\u00fcller-Sienerth, N. et al. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS ONE 6, e21556 (2011).","journal-title":"PLoS ONE"},{"key":"70133_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2007.05.006","volume":"26","author":"M Lu","year":"2007","unstructured":"Lu, M. et al. XIAP induces NF-kappaB activation via the BIR1\/TAB1 interaction and BIR1 dimerization. Mol. Cell 26, 689\u2013702 (2007).","journal-title":"Mol. Cell"},{"key":"70133_CR38","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","volume":"26","author":"MM Mita","year":"2020","unstructured":"Mita, M. M. et al. A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma. Clin. Cancer Res. 26, 2819 (2020).","journal-title":"Clin. Cancer Res."},{"key":"70133_CR39","doi-asserted-by":"crossref","unstructured":"Michot, J. M. et al. S217: preliminary analysis of the phase II study using tolinapant (Astx660) monotherapy in 98 peripheral T-cell lymphoma and 51 cutaneous T-cell lymphoma subjects with relapsed refractory disease. HemaSphere 6, 118\u2013119 (2022).","DOI":"10.1097\/01.HS9.0000843760.14993.43"},{"key":"70133_CR40","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1182\/blood-2023-179195","volume":"142","author":"B Poligone","year":"2023","unstructured":"Poligone, B. et al. ASTX660-01 phase 2: a case study of tolinapant-induced pseudoprogression in CTCL. Blood 142, 6205 (2023).","journal-title":"Blood"},{"key":"70133_CR41","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1021\/acs.jmedchem.8b00900","volume":"61","author":"CN Johnson","year":"2018","unstructured":"Johnson, C. N. et al. A fragment-derived clinical candidate for antagonism of X-linked and cellular inhibitor of apoptosis proteins: 1-(6-[(4-fluorophenyl)methyl]\u22125-(hydroxymethyl)\u22123,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)\u22122-[(2R,5R)\u22125-methyl-2-([(3R)\u22123-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660). J. Med. Chem. 61, 7314\u20137329 (2018).","journal-title":"J. Med. Chem."},{"key":"70133_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/path.2124","volume":"211","author":"A McCarthy","year":"2007","unstructured":"McCarthy, A. et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 211, 389\u2013398 (2007).","journal-title":"J. Pathol."},{"key":"70133_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.stem.2010.07.010","volume":"7","author":"G Molyneux","year":"2010","unstructured":"Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403\u2013417 (2010).","journal-title":"Cell Stem Cell"},{"key":"70133_CR44","doi-asserted-by":"crossref","unstructured":"Fedele, M., Cerchia, L. & Chiappetta, G. The epithelial-to-mesenchymal transition in breast cancer: focus on basal-like carcinomas. Cancers 9, 134 (2017).","DOI":"10.3390\/cancers9100134"},{"key":"70133_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7571","volume":"14","author":"EM Grasset","year":"2022","unstructured":"Grasset, E. M. et al. Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. Sci. Transl. Med. 14, eabn7571 (2022).","journal-title":"Sci. Transl. Med."},{"key":"70133_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1083\/jcb.200503144","volume":"171","author":"MJ Naylor","year":"2005","unstructured":"Naylor, M. J. et al. Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J. Cell Biol. 171, 717\u2013728 (2005).","journal-title":"J. Cell Biol."},{"key":"70133_CR47","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner, N., Tutt, A. & Ashworth, A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat. Rev. Cancer 4, 814\u2013819 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"70133_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10911-011-9202-8","volume":"16","author":"G Molyneux","year":"2011","unstructured":"Molyneux, G. & Smalley, M. J. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling. J. Mammary Gland Biol. Neoplasia 16, 51\u201355 (2011).","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"70133_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2776","volume":"12","author":"N Tung","year":"2010","unstructured":"Tung, N. et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 12, R95 (2010).","journal-title":"Breast Cancer Res."},{"key":"70133_CR50","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. Identification of genes associated with prognosis and immunotherapy prediction in triple-negative breast cancer via M1\/M2 macrophage ratio. Medicina 59, 1285 (2023).","DOI":"10.3390\/medicina59071285"},{"key":"70133_CR51","doi-asserted-by":"publisher","first-page":"643771","DOI":"10.3389\/fimmu.2021.643771","volume":"12","author":"AK Mehta","year":"2021","unstructured":"Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M. & Guerriero, J. L. Macrophage biology and mechanisms of immune suppression in breast cancer. Front. Immunol. 12, 643771 (2021).","journal-title":"Front. Immunol."},{"key":"70133_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta, A. K. et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat. Cancer 2, 66\u201382 (2021).","journal-title":"Nat. Cancer"},{"key":"70133_CR53","doi-asserted-by":"crossref","unstructured":"Gilmore, T. D. NF-\u03baB and human cancer: what have we learned over the past 35 years? Biomedicines 9, 889 (2021).","DOI":"10.3390\/biomedicines9080889"},{"key":"70133_CR54","doi-asserted-by":"crossref","unstructured":"Kearney, C. J. et al. Tumor immune evasion arises through loss of TNF sensitivity. Sci. Immunol. 3, eaar3451 (2018).","DOI":"10.1126\/sciimmunol.aar3451"},{"key":"70133_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.01.005","volume":"180","author":"DW Vredevoogd","year":"2020","unstructured":"Vredevoogd, D. W. et al. Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell 180, 404\u2013405 (2020).","journal-title":"Cell"},{"key":"70133_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","volume":"82","author":"SA DuPre","year":"2007","unstructured":"DuPre, S. A. & Hunter, K. W. Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp. Mol. Pathol. 82, 12\u201324 (2007).","journal-title":"Exp. Mol. Pathol."},{"key":"70133_CR57","doi-asserted-by":"crossref","unstructured":"Meier, P., Legrand, A. J., Adam, D. & Silke, J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer 24, 299\u2013315 (2024).","DOI":"10.1038\/s41568-024-00674-x"},{"key":"70133_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559\u2013569 (2019).","journal-title":"J. Clin. Oncol."},{"key":"70133_CR59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687\u2013692 (2015).","journal-title":"Clin. Cancer Res."},{"key":"70133_CR60","doi-asserted-by":"crossref","unstructured":"Mannion, J. et al. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity 57, 1514\u20131532.e15 (2024).","DOI":"10.1016\/j.immuni.2024.04.025"},{"key":"70133_CR61","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed, A. & Tait, S. W. G. Targeting immunogenic cell death in cancer. Mol. Oncol. 14, 2994\u20133006 (2020).","journal-title":"Mol. Oncol."},{"key":"70133_CR62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"70133_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"70133_CR64","doi-asserted-by":"crossref","unstructured":"Morrish, E., Brumatti, G. & Silke, J. Future therapeutic directions for Smac-mimetics. Cells 9, 406 (2020).","DOI":"10.3390\/cells9020406"},{"key":"70133_CR65","first-page":"95","volume":"403","author":"J Silke","year":"2017","unstructured":"Silke, J. & Vince, J. IAPs and cell death. Curr. Top. Microbiol. Immunol. 403, 95\u2013117 (2017).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"70133_CR66","doi-asserted-by":"crossref","unstructured":"Silke, J. & Meier, P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb. Perspect. Biol. 5, a008730 (2013).","DOI":"10.1101\/cshperspect.a008730"},{"key":"70133_CR67","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.it.2023.05.007","volume":"44","author":"J Huyghe","year":"2023","unstructured":"Huyghe, J., Priem, D. & Bertrand, M. J. M. Cell death checkpoints in the TNF pathway. Trends Immunol. 44, 628\u2013643 (2023).","journal-title":"Trends Immunol."},{"key":"70133_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmed.2017.11.002","volume":"24","author":"A Annibaldi","year":"2018","unstructured":"Annibaldi, A. & Meier, P. Checkpoints in TNF-induced cell death: implications in inflammation and cancer. Trends Mol. Med. 24, 49\u201365 (2018).","journal-title":"Trends Mol. Med."},{"key":"70133_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-019-1830-y","volume":"577","author":"P Tao","year":"2020","unstructured":"Tao, P. et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature 577, 109\u2013114 (2020).","journal-title":"Nature"},{"key":"70133_CR70","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-019-1828-5","volume":"577","author":"N Lalaoui","year":"2020","unstructured":"Lalaoui, N. et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature 577, 103\u2013108 (2020).","journal-title":"Nature"},{"key":"70133_CR71","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1548-x","volume":"574","author":"K Newton","year":"2019","unstructured":"Newton, K. et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature 574, 428\u2013431 (2019).","journal-title":"Nature"},{"key":"70133_CR72","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.molcel.2018.11.010","volume":"73","author":"G Liccardi","year":"2019","unstructured":"Liccardi, G. et al. RIPK1 and caspase-8 ensure chromosome stability independently of their role in cell death and inflammation. Mol. Cell 73, 413\u2013428.e417 (2019).","journal-title":"Mol. Cell"},{"key":"70133_CR73","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","volume":"564","author":"JM Ramanjulu","year":"2018","unstructured":"Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439\u2013443 (2018).","journal-title":"Nature"},{"key":"70133_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754436","volume":"12","author":"E Appleton","year":"2021","unstructured":"Appleton, E. et al. Kickstarting immunity in cold tumours: localised tumour therapy combinations with immune checkpoint blockade. Front. Immunol. 12, 754436 (2021).","journal-title":"Front. Immunol."},{"key":"70133_CR75","doi-asserted-by":"crossref","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci. Transl. Med. 11, eaav7816 (2019).","DOI":"10.1126\/scitranslmed.aav7816"},{"key":"70133_CR76","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fimmu.2020.00223","volume":"11","author":"RM Zemek","year":"2020","unstructured":"Zemek, R. M. et al. Sensitizing the tumor microenvironment to immune checkpoint therapy. Front. Immunol. 11, 223 (2020).","journal-title":"Front. Immunol."},{"key":"70133_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41590-019-0556-1","volume":"21","author":"A Ablasser","year":"2020","unstructured":"Ablasser, A. & Hur, S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat. Immunol. 21, 17\u201329 (2020).","journal-title":"Nat. Immunol."},{"key":"70133_CR78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4939-2297-0_3","volume":"1267","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto, K., Schmidt, J. W. & Wagner, K. U. Mouse models of breast cancer. Methods Mol. Biol. 1267, 47\u201371 (2015).","journal-title":"Methods Mol. Biol."},{"key":"70133_CR79","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065\u20131073 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"70133_CR80","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm.3802","volume":"21","author":"M Matano","year":"2015","unstructured":"Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256\u2013262 (2015).","journal-title":"Nat. Med."},{"key":"70133_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature14415","volume":"521","author":"J Drost","year":"2015","unstructured":"Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43\u201347 (2015).","journal-title":"Nature"},{"key":"70133_CR82","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"70133_CR83","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nbt.3836","volume":"35","author":"J Roper","year":"2017","unstructured":"Roper, J. et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat. Biotechnol. 35, 569\u2013576 (2017).","journal-title":"Nat. Biotechnol."},{"key":"70133_CR84","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nbt.3837","volume":"35","author":"KP O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, K. P. et al. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat. Biotechnol. 35, 577\u2013582 (2017).","journal-title":"Nat. Biotechnol."},{"key":"70133_CR85","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","volume":"19","author":"L Mifflin","year":"2020","unstructured":"Mifflin, L., Ofengeim, D. & Yuan, J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat. Rev. Drug Discov. 19, 553\u2013571 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70133_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molmed.2018.10.007","volume":"25","author":"V Kondylis","year":"2019","unstructured":"Kondylis, V. & Pasparakis, M. RIP kinases in liver cell death, inflammation and cancer. Trends Mol. Med. 25, 47\u201363 (2019).","journal-title":"Trends Mol. Med."},{"key":"70133_CR87","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.1073\/pnas.1901179116","volume":"116","author":"A Degterev","year":"2019","unstructured":"Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. Proc. Natl. Acad. Sci. USA 116, 9714\u20139722 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70133_CR88","doi-asserted-by":"publisher","first-page":"e975093","DOI":"10.4161\/23723556.2014.975093","volume":"2","author":"T Vanden Berghe","year":"2015","unstructured":"Vanden Berghe, T., Kaiser, W. J., Bertrand, M. J. & Vandenabeele, P. Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol. Cell Oncol. 2, e975093 (2015).","journal-title":"Mol. Cell Oncol."},{"key":"70133_CR89","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ni.3206","volume":"16","author":"J Silke","year":"2015","unstructured":"Silke, J., Rickard, J. A. & Gerlic, M. The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol. 16, 689\u2013697 (2015).","journal-title":"Nat. Immunol."},{"key":"70133_CR90","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1083\/jcb.200801010","volume":"182","author":"JE Vince","year":"2008","unstructured":"Vince, J. E. et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.  J. Cell Biol. 182, 171\u2013184 (2008).","journal-title":"J. Cell Biol."},{"key":"70133_CR91","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/ni.1678","volume":"9","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9, 1364\u20131370 (2008).","journal-title":"Nat. Immunol."},{"key":"70133_CR92","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"70133_CR93","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"70133_CR94","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","volume":"131","author":"JE Vince","year":"2007","unstructured":"Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682\u2013693 (2007).","journal-title":"Cell"},{"key":"70133_CR95","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2007.08.029","volume":"12","author":"SL Petersen","year":"2007","unstructured":"Petersen, S. L. et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445\u2013456 (2007).","journal-title":"Cancer Cell"},{"key":"70133_CR96","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1172\/JCI33522","volume":"118","author":"B Zhang","year":"2008","unstructured":"Zhang, B., Karrison, T., Rowley, D. A. & Schreiber, H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118, 1398\u20131404 (2008).","journal-title":"J. Clin. Invest."},{"key":"70133_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neo.2018.11.002","volume":"21","author":"AK Knuth","year":"2019","unstructured":"Knuth, A. K. et al. Interferons transcriptionally up-regulate MLKL expression in cancer cells. Neoplasia 21, 74\u201381 (2019).","journal-title":"Neoplasia"},{"key":"70133_CR98","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","volume":"178","author":"DW Vredevoogd","year":"2019","unstructured":"Vredevoogd, D. W. et al. Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell 178, 585\u2013599.e515 (2019).","journal-title":"Cell"},{"key":"70133_CR99","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"70133_CR100","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nature09852","volume":"471","author":"A Oberst","year":"2011","unstructured":"Oberst, A. et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471, 363\u2013367 (2011).","journal-title":"Nature"},{"key":"70133_CR101","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.celrep.2012.03.010","volume":"1","author":"CP Dillon","year":"2012","unstructured":"Dillon, C. P. et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 1, 401\u2013407 (2012).","journal-title":"Cell Rep."},{"key":"70133_CR102","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature09857","volume":"471","author":"WJ Kaiser","year":"2011","unstructured":"Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368\u2013372 (2011).","journal-title":"Nature"},{"key":"70133_CR103","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1101\/gad.13.19.2514","volume":"13","author":"Y Lin","year":"1999","unstructured":"Lin, Y., Devin, A., Rodriguez, Y. & Liu, Z. G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13, 2514\u20132526 (1999).","journal-title":"Genes Dev."},{"key":"70133_CR104","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.celrep.2019.07.077","volume":"28","author":"SL Orozco","year":"2019","unstructured":"Orozco, S. L. et al. RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. Cell Rep. 28, 2275\u20132287.e2275 (2019).","journal-title":"Cell Rep."},{"key":"70133_CR105","doi-asserted-by":"crossref","unstructured":"Snyder, A. G. et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol. 4, eaaw2004 (2019).","DOI":"10.1126\/sciimmunol.aaw2004"},{"key":"70133_CR106","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s42003-020-01362-w","volume":"3","author":"ST Workenhe","year":"2020","unstructured":"Workenhe, S. T. et al. De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Commun. Biol. 3, 645 (2020).","journal-title":"Commun. Biol."},{"key":"70133_CR107","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","volume":"15","author":"TL Aaes","year":"2016","unstructured":"Aaes, T. L. et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15, 274\u2013287 (2016).","journal-title":"Cell Rep."},{"key":"70133_CR108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"70133_CR109","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).","journal-title":"PLoS Biol."},{"key":"70133_CR110","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nmeth.4535","volume":"15","author":"AA Duarte","year":"2018","unstructured":"Duarte, A. A. et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat. Methods 15, 134\u2013140 (2018).","journal-title":"Nat. Methods"},{"key":"70133_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13207","volume":"7","author":"T Jarde","year":"2016","unstructured":"Jarde, T. et al. Wnt and Neuregulin1\/ErbB signalling extends 3D culture of hormone responsive mammary organoids. Nat. Commun. 7, 13207 (2016).","journal-title":"Nat. Commun."},{"key":"70133_CR112","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.celrep.2018.03.054","volume":"23","author":"R Feltham","year":"2018","unstructured":"Feltham, R. et al. Mind bomb regulates cell death during TNF signaling by suppressing RIPK1\u2019s cytotoxic potential. Cell Rep. 23, 470\u2013484 (2018).","journal-title":"Cell Rep."},{"key":"70133_CR113","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"70133_CR114","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","volume":"28","author":"V Boeva","year":"2012","unstructured":"Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423\u2013425 (2012).","journal-title":"Bioinformatics"},{"key":"70133_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43242-x","volume":"14","author":"A Fitzpatrick","year":"2023","unstructured":"Fitzpatrick, A. et al. Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nat. Commun. 14, 7408 (2023).","journal-title":"Nat. Commun."},{"key":"70133_CR116","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"70133_CR117","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett, S. W. & Andrews, S. FastQ screen: a tool for multi-genome mapping and quality control. F1000Res 7, 1338 (2018).","journal-title":"F1000Res"},{"key":"70133_CR118","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"70133_CR119","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"70133_CR120","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","volume":"41","author":"JS Parker","year":"2023","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 41, 4192\u20134199 (2023).","journal-title":"J. Clin. Oncol."},{"key":"70133_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-11-r125","volume":"14","author":"AD Pfefferle","year":"2013","unstructured":"Pfefferle, A. D. et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 14, R125 (2013).","journal-title":"Genome Biol."},{"key":"70133_CR122","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jnci\/dju357","volume":"107","author":"ER Paquet","year":"2015","unstructured":"Paquet, E. R. & Hallett, M. T. Absolute assignment of breast cancer intrinsic molecular subtype. J. Natl. Cancer Inst. 107, 357 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"70133_CR123","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","volume":"20","author":"AS Castanza","year":"2023","unstructured":"Castanza, A. S. et al. Extending support for mouse data in the Molecular Signatures Database (MSigDB). Nat. Methods 20, 1619\u20131620 (2023).","journal-title":"Nat. Methods"},{"key":"70133_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21783-3","volume":"12","author":"K Bach","year":"2021","unstructured":"Bach, K. et al. Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nat. Commun. 12, 1502 (2021).","journal-title":"Nat. Commun."},{"key":"70133_CR125","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"70133_CR126","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202211490","volume":"19","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Multisite assessment of reproducibility in high-content cell migration imaging data. Mol. Syst. Biol. 19, e11490 (2023).","journal-title":"Mol. Syst. Biol."},{"key":"70133_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-9-13","volume":"9","author":"D Robertson","year":"2008","unstructured":"Robertson, D., Savage, K., Reis-Filho, J. S. & Isacke, C. M. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 9, 13 (2008).","journal-title":"BMC Cell Biol."},{"key":"70133_CR128","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s44321-024-00074-6","volume":"16","author":"S Chiou","year":"2024","unstructured":"Chiou, S. et al. An immunohistochemical atlas of necroptotic pathway expression. EMBO Mol. Med. 16, 1717\u20131749 (2024).","journal-title":"EMBO Mol. Med."},{"key":"70133_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70133-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:05:10Z","timestamp":1776668710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70133"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70133-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3597"}}